IRWD
Ironwood Pharmaceuticals Inc
4.10$
-1.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 86.9% | 80.8% | 53.6% | 51.4% | 80.2% | 76.2% | 88.7% | 66.1% | 70.9% | 49.5% | 52.0% | 69.1% | |
| 22.3% | 42.2% | 7.6% | 20.8% | 52.2% | 44.0% | 65.1% | 55.0% | 59.6% | 19.6% | 25.2% | 54.3% | |
| 74.5% | 71.0% | 43.0% | 36.6% | 52.2% | 44.0% | 65.1% | 55.0% | 59.6% | 19.6% | 25.2% | 54.3% | |
| 7.7% | 8.8% | 9.1% | 13.6% | 24.4% | 29.1% | 21.9% | 10.1% | 10.5% | 27.4% | 23.3% | 11.8% | |
| 1.5% | 0.0% | 0.2% | 0.1% | 0.0% | 0.2% | 0.0% | 0.1% | 0.1% | 0.0% | – | – | |
| 8.9% | 3.4% | 2.9% | 2.9% | 5.2% | 3.1% | 1.6% | 2.0% | 0.6% | – | – | – | |
| 0.0% | 0.0% | 0.1% | 0.1% | 0.2% | 0.2% | 0.1% | – | – | – | – | – | |
| 0.0% | 0.0% | 23.4% | 26.4% | – | – | – | – | – | 0.8% | 0.8% | 0.5% | |
| 73.4% | 84.6% | 90.6% | 98.4% | 159.1% | 123.2% | 88.8% | 46.2% | 40.7% | 173.5% | 185.9% | 166.0% | |
| 18.2% | 12.4% | 12.8% | 10.9% | 36.0% | 10.2% | 5.8% | 14.3% | 2.3% | 58.6% | 11.1% | 61.0% | |
| 4.1% | 4.9% | 0.9% | 0.7% | 14.3% | 0.3% | 0.6% | 10.6% | 0.3% | 43.0% | 0.9% | 51.1% | |
| 2.9% | 1.4% | 2.5% | 2.6% | 4.5% | 1.4% | 0.1% | 0.1% | 0.0% | 1.7% | 0.6% | 0.7% | |
| 48.7% | 57.1% | 51.6% | 65.4% | 110.3% | 101.3% | 76.9% | 29.9% | 36.0% | 105.8% | 166.4% | 97.0% | |
| 26.6% | 15.4% | 9.4% | 1.6% | -59.1% | -23.2% | 11.2% | 53.8% | 59.3% | -73.5% | -85.9% | -66.0% | |
| -290.1% | -179.3% | -167.9% | -216.1% | -479.2% | -390.4% | -262.2% | -83.2% | -63.3% | -360.6% | -483.8% | -421.7% | |
| 41.0% | 23.0% | 20.6% | 24.6% | 46.0% | 38.7% | 28.7% | 14.6% | 16.9% | 33.0% | 45.6% | 44.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.